Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares IssuedShort-Term Debt issuancesShort-Term Debt repayments
Daily Values
Growth Metrics
Income Statement
Others
Ratios

United Therapeutics (UTHR) Other financing activities (2016 - 2025)

United Therapeutics (UTHR) has disclosed Other financing activities for 16 consecutive years, with $11.5 million as the latest value for Q2 2025.

  • Quarterly Other financing activities changed N/A to $11.5 million in Q2 2025 from the year-ago period, while the trailing twelve-month figure was $11.5 million through Dec 2025, up 325.93% year-over-year, with the annual reading at $11.5 million for FY2025, 325.93% up from the prior year.
  • Other financing activities hit $11.5 million in Q2 2025 for United Therapeutics, up from $2.7 million in the prior quarter.
  • In the past five years, Other financing activities ranged from a high of $11.5 million in Q2 2025 to a low of $2.7 million in Q1 2023.
  • Historically, Other financing activities has averaged $6.1 million across 4 years, with a median of $5.1 million in 2022.
  • Biggest five-year swings in Other financing activities: tumbled 64.0% in 2023 and later changed 0.0% in 2024.
  • Year by year, Other financing activities stood at $7.5 million in 2022, then crashed by 64.0% to $2.7 million in 2023, then changed by 0.0% to $2.7 million in 2024, then soared by 325.93% to $11.5 million in 2025.
  • Business Quant data shows Other financing activities for UTHR at $11.5 million in Q2 2025, $2.7 million in Q1 2024, and $2.7 million in Q1 2023.